MedTrace Logo

Effect Of Sodium Glucose Co-Transporter-2 (SGLT-2) Inhibitors on Body Mass Index After 3 Months of Use in Diabetic Patients

NCT07367555 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 360

Last updated 2026-01-26

No results posted yet for this study

Summary

Total of 360 participants were enrolled and prescribed oral 200 mg SGLT-2 tablet. All participants were followed-up for about three months. Body mass index was measured before and after three months and mean change in BMI was assessed.

Conditions

  • Diabete Mellitus

Interventions

DRUG

Oral 100 gram Empagliflozin tablet along with diet plan and exercise

oral 100 gram Empagliflozin tablet along with diet plan and exercise

OTHER

Diet plan and exercise

Only Life style modification was advised. Changes in BMI were assessed.

Sponsors & Collaborators

  • Ariba Shafiq

    lead OTHER

Principal Investigators

  • Professor Dr Khalid Mehmood Raja, MBBS FCPS · CMH Multan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-01
Primary Completion
2025-03-31
Completion
2025-03-31

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07367555 on ClinicalTrials.gov